Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 15Neoplasms 3Sarcoma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Uterine Neoplasms 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Recurrence 1Peritoneal Neoplasms 1Ovarian Epithelial Cancer Recurrent 1Ovarian Diseases 1Neurofibrosarcoma 1Neoplasms by Site 1Malignant mesenchymal tumor 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Genital Diseases, Female 1Gastrointestinal Stromal Tumors 1Fibrosarcoma 1Fanconi Anemia, Complementation Group D1 1Endocrine Gland Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 28Paclitaxel 24Cisplatin 23Oxaliplatin 18Cytoreduction Surgical Procedures 17Carboplatin 17Fluorouracil 14Bevacizumab 10Mitomycin 9Leucovorin 9Doxorubicin 9Docetaxel 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Neoadjuvant Therapy 4Laparoscopy 4Blood Specimen Collection 4Albumin-Bound Paclitaxel 4sodium thiosulfate 3liposomal doxorubicin 3catumaxomab 3Taxes 3Drug Therapy 3Chemotherapy, Adjuvant 3tremelimumab 2relacorilant 2pembrolizumab 2olaparib 2nintedanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Trabectedin × Gynecologic × Clear all
NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Janssen Research & Development, LLC

Phase 3 Completed
581 enrolled 14 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡